Francois-xavier Otte

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

Journal: European urology oncology

Published: December 12, 2025

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

Journal: European urology oncology

Published: December 12, 2025

Exploration of Predictive Factors for Acute Radiotherapy-Induced Gastro-Intestinal Symptoms in Prostate Cancer Patients.

Exploration of Predictive Factors for Acute Radiotherapy-Induced Gastro-Intestinal Symptoms in Prostate Cancer Patients.

Journal: Cancers

Published: November 09, 2025

Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial.

Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial.

Journal: European urology oncology

Published: October 01, 2025

Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial.

Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial.

Journal: The Lancet. Oncology

Published: February 11, 2025

PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.

PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.

Journal: European urology oncology

Published: May 17, 2023

Lymphocyte-sparing pelvic radiotherapy for prostate cancer: An in-silico study.

Lymphocyte-sparing pelvic radiotherapy for prostate cancer: An in-silico study.

Journal: Physics and imaging in radiation oncology

Published: April 12, 2022

Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.

Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: January 30, 2022

Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact.

Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact.

Journal: Cancers

Published: August 29, 2021

Evaluation of the XVI dual registration tool for image-guided radiotherapy in prostate cancer.

Evaluation of the XVI dual registration tool for image-guided radiotherapy in prostate cancer.

Journal: Technical innovations & patient support in radiation oncology

Published: December 22, 2020

Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.

Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.

Journal: Future oncology (London, England)

Published: May 02, 2020

PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.

PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.

Journal: BMC cancer

Published: March 23, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026